What 3billion does

3billion, Inc. is a Seoul-headquartered, KOSDAQ-listed (ticker: 3BIONE) clinical genomics company founded in October 2016 that delivers AI-powered rare-disease diagnostics to healthcare providers and patients globally. Its core offering is a sequencing-and-interpretation stack: 3B-GENOME (WGS) and 3B-EXOME (WES) diagnostic tests with a 5-week turnaround, 3B-VARIANT (Sanger confirmation), and 3B-INTERPRETER for labs that perform their own sequencing and submit FASTQ data. The diagnostic engine rests on four proprietary AI systems — EVIDENCE for ACMG-aligned variant interpretation (98.4% sensitivity, 99.9% specificity), 3Cnet for variant pathogenicity prediction (2.2x higher sensitivity than alternatives), the GEBRA SaaS platform for end-to-end interpretation (99.4% accuracy, 20-minute WES turnaround), and MIN-T for AI-driven drug discovery (95% synthesis confirmability). All diagnostic tests include automated, weekly reanalysis of negative and inconclusive cases at no additional cost, generating 954+ additional diagnoses since 2024.

The company monetizes through a mix of one-time test fees (B2B via a healthcare-provider portal serving 2,100+ providers and 790+ institutions across 75+ countries), recurring SaaS subscriptions for GEBRA, an End the Diagnostic Odyssey grant program providing free WGS/WES to eligible pediatric patients, and emerging pharma collaborations. The 2025-2026 product launches (Family Insight Test in March 2026, 3B-NEO genomic newborn screening covering 595 genes in June 2026) extend the platform from rare-disease diagnosis into proactive reproductive and newborn health. With a $225M USD post-IPO capital raise in April 2026 and a $8.1M US subsidiary buildout in Austin, Texas (3billion US, Inc., 200 jobs planned by 2026), the company is scaling from a Korea-export diagnostic model into a multi-region, multi-product clinical AI platform backed by CAP, CLIA, ISO/IEC 27001:2022, and HIPAA-on-AWS compliance.

Name

3billion

Legal name

3billion, Inc.

Website

https://3billion.io

Company type

Public

Founded year

2016

Operating status

Operating

Headcount range

51–100 employees

Short description

3billion is an AI-powered genomic diagnostics company providing rare disease identification, family-based testing, and newborn screening through WGS/WES sequencing, proprietary variant interpretation (EVIDENCE, 3Cnet, GEBRA), and a SaaS platform, serving 2,100+ healthcare providers across 75+ countries.

Ownership category

akta.pro rank

Product category

Clinical Genomics & Rare Disease Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genetic & Prenatal Testing Laboratories (HLAFAMAH)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Rare disease diagnostics
• Clinical genomic testing
• AI variant interpretation
• Whole genome sequencing
• Newborn genetic screening

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Whole Genome Sequencing (3B-GENOME): Full WGS-based genetic testing service with TAT of 5 weeks, including automated reanalysis. Detects SNV, INDEL, SV (including CNV), and mitochondrial DNA variants. Primary diagnostic service for complex rare disease cases.
2. Whole Exome Sequencing (3B-EXOME): WES-based genetic testing service with TAT of 5 weeks, including automated reanalysis. Covers approximately 20,000 genes with enhanced depth and coverage (Boosted Exome V2 with up to 2000x mitochondrial coverage). Primary first-line test for rare disease diagnosis.
3. 3B-VARIANT (Sanger Sequencing): Targeted Sanger sequencing service to reconfirm specific variants detected by 3B-GENOME or 3B-EXOME. TAT of 2 weeks. Used for family member confirmation and family planning.
4. 3B-INTERPRETER: Data-based genomic analysis and interpretation service from uploaded FASTQ data. TAT of 2 weeks. Revenue stream from labs sending raw sequencing data for clinical reporting.
5. 3B-NEO Newborn Screening: Genomic newborn screening service covering 595 genes (WES or WGS options) with TAT of ~2 weeks. Available as standard (WES) or premium (WGS) plans. Targets maternity hospitals, obstetrics practices, pediatric clinics, and families. Launched June 2026.
6. Family Insight Test: Family-based WGS/WES precision genomic testing service launched March 2026. Adds carriership findings for families facing reproductive challenges or inherited risks. Covers reproductive loss, genetic legacy, alternative path, and consanguinity use cases.
7. GEBRA SaaS Platform: AI-powered variant interpretation SaaS platform offered to medical geneticists and diagnostic labs. Implements HIPAA-compliant cloud-native architecture on AWS. Revenue from SaaS subscription/licensing to clinical labs and institutions.

Pricing tiers

Go-to-market motion4 records

Distribution channels5 records

Marketing channels8 records

Core offering

3billion provides AI-powered clinical genomic testing and interpretation services for rare disease diagnosis and newborn screening. Its core offerings include whole-genome sequencing (3B-GENOME), whole-exome sequencing (3B-EXOME), targeted Sanger variant confirmation (3B-VARIANT), automated variant interpretation (3B-INTERPRETER), and a family/newborn screening panel (3B-NEO). The company also licenses GEBRA, a SaaS variant interpretation and clinical reporting platform, to external diagnostic laboratories.

Product overview

3billion offers a comprehensive genetic testing platform consisting of diagnostic sequencing products (3B-GENOME for WGS, 3B-EXOME for WES, 3B-VARIANT for Sanger sequencing), data interpretation services (3B-INTERPRETER for uploaded data analysis), and the AI-powered GEBRA™ interpretation platform. The portfolio expands into proactive healthcare with 3B-NEO genomic newborn screening (595 genes) and the Family Insight Test for family-based analysis. Core AI technologies include EVIDENCE (automated variant interpretation), 3Cnet (pathogenicity prediction), and MIN-T (drug discovery). All diagnostic products include automated reanalysis at no additional cost. Services are accessed through a web portal with results delivered within 2-5 weeks depending on test type.

Differentiator

Problem solved

Functional benefit

Brands

• 3B-GENOME: Whole genome sequencing-based genetic testing service
• 3B-EXOME
• 3B-VARIANT
• 3B-INTERPRETER
• GEBRA
• 3B-NEO
• Family Insight Test

Products and services

• 3B-GENOME Clinical whole-genome sequencing (WGS) test for rare disease diagnosis, using AI-augmented variant interpretation and ACMG-aligned reporting for healthcare providers.
• 3B-EXOME Clinical whole-exome sequencing (WES) test for rare disease diagnosis with AI-driven interpretation, targeting pediatric and neurology genetic cases.
• 3B-VARIANT Targeted Sanger sequencing confirmation service for previously identified variants, used by clinicians for orthogonal validation of NGS findings.
• 3B-INTERPRETER Automated clinical variant interpretation service that applies ACMG guidelines and 3billion's AI models to produce clinically actionable reports for healthcare providers.
• 3B-NEO Newborn genetic screening panel for early detection of treatable inherited disorders, offered to families and pediatric care providers.
• Family Insight Test Family-based genetic testing service that analyzes variants across multiple family members (typically trio analysis) to resolve variants of uncertain significance in rare disease cases.
• GEBRA SaaS variant interpretation and clinical reporting platform licensed to external diagnostic laboratories, providing ACMG-classified variant interpretation, automated clinical report generation, and reanalysis workflows.

Quantifiable outcome

• 98.4% sensitivity and 99.9% specificity in variant interpretation (EVIDENCE vs ClinVar)
• +7 more outcomes

Named customers20 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Partnerships

Nine partnerships are on record, tiered minor, core and strategic.

• CEPCAL (Colaborativa para Enfermedades Poco Frecuentes en el Caribe y América Latina)minorStrategic or Co-development Partner · 1 June 20263billion announced participation in CEPCAL 2026, taking place June 17-19, 2026 in Antigua, Guatemala. CEPCAL is a collaborative initiative for rare diseases in the Caribbean and Latin America. 3billion will connect with clinicians, researchers, laboratory professionals, and healthcare partners from Latin America and the Caribbean to explore how genetic testing can support their practice or research.
• European Society of Human Genetics (ESHG)minorStrategic or Co-development Partner · 1 June 20263billion attending ESHG Conference 2026 in Gothenburg, Sweden (June 13-16, Booth #620). Presenting comprehensive genetic testing services, 3B-NEO newborn screening, and Family Insight Test. Opportunity to connect with clinical geneticists and genomic specialists across Europe.
• Genomic and Genetic Technologies in Clinical Practice Conference 2026minorStrategic or Co-development Partner · 1 June 20263billion attending conference at Narxoz Business School in Almaty, Kazakhstan (June 3-4, 2026). Two presentations: 'Expanding Rare Disease Diagnosis: 3billion's Evolving Genetic Solutions' by Minsoo Kim and 'The Clinical Impact of Reanalysis in Rare Diseases' by Yoo Hyun Kim.
• ACMG (American College of Medical Genetics and Genomics)minorStrategic or Co-development Partner · 11 March 20263billion showcased its AI-powered variant interpretation platform GEBRA at ACMG 2026 conference in Baltimore, Maryland (March 2026). Demonstrated the platform's capabilities to clinical geneticists and researchers worldwide as part of its efforts to expand global presence and strengthen technical leadership in genetic diagnostics.
• Genetic Alliance (iHope Program)coreStrategic or Co-development Partner3billion selected as first official laboratory partner in Asia for Genetic Alliance's iHope program (March 2026). Provides precision diagnostics for pediatric rare disease patients in developing nations, helping reduce prolonged diagnostic odysseys. 3billion contributes its AI-powered variant interpretation platform (GEBRA) and operational infrastructure spanning 75+ countries. Expands 3billion's role in the global rare disease diagnostic ecosystem and advances equitable access to precision medicine worldwide.
• Amazon Web Services (AWS)coreTechnology or Integration3billion implemented GEBRA as a SaaS platform using AWS cloud infrastructure with HIPAA compliance. Leveraged AWS cloud security tools to address varying data governance standards across countries and established a cloud-native environment for processing large-scale genomic data. Participated as speaker at AWS HealthTech Global Expansion Seminar 2026 (April 28) sharing its experience with global market expansion. Also showcased AI genomic interpretation SaaS at AWS Public Sector Day 2025.
• Embassy of Argentina in SeoulstrategicStrategic or Co-development Partner3billion conducted an official visit to the Embassy of Argentina in Seoul (April 2026) to discuss strategic cooperation aimed at expanding precision medicine networks in South America. Meeting with Ambassador Darío Celaya focused on building equitable medical systems and delivering diagnostic solutions to rare disease patients in Argentina and beyond. Plans to strengthen partnerships advancing practical diagnostic solutions in the region.
• Over 400 Global Healthcare and Research InstitutionscoreChannel Partner/ Reseller/ Distributor3billion collaborates with over 400 healthcare and research institutions globally including Seoul National University Hospital, Samsung Changwon Hospital, Hospital Kuala Lumpur, Hospital Regional de Antofagasta, Universidade Federal de Sao Paulo, University of Malaya, and others across 70+ countries. These institutions order genetic tests through the 3billion portal and serve as the primary distribution channel for diagnostic services.
• City of Austin, TexasstrategicOthersAustin City Council approved a 10-year expansion agreement with 3billion US, Inc. in February 2026, involving $8.1M capital investment and creation of 200 full-time jobs. City offered $200,000 incentive ($1,000 per job created) to establish the first North American genetic testing laboratory in Austin.

Scale indicators14 records

Recent moves8 records

Expansion highlights10 records

Direct peers

• Centogene: Centogene is a rare disease diagnostics company with similar focus on rare disease genetic testing, biomarker discovery, and global operations. Direct competitor in rare disease genomics with parallel target market of patients and pharmaceutical partners.
• Sophia Genetics: Sophia Genetics is an AI-driven genomic and clinical data analysis company serving hospitals and labs. Direct peer in AI-powered genomic interpretation SaaS with similar business model of providing variant interpretation technology to clinical institutions.
• GeneDx: GeneDx is a leading US-based clinical genetic testing company specializing in rare disease diagnosis using whole exome and genome sequencing. Direct competitor in rare disease genetic diagnostics with similar AI-driven interpretation focus and established US market presence.
• PreventionGenetics: PreventionGenetics is a clinical DNA testing laboratory offering whole genome, exome, and targeted genetic tests for rare disorders. Direct peer in clinical genetic testing with focus on hereditary and rare disease diagnostics.
• Invitae (now Labcorp): Invitae, acquired by Labcorp, was a major genetic testing company offering comprehensive genetic tests including rare disease panels. Direct competitor in clinical genetic testing with much larger US footprint and broader test menu.
• Variantyx: Variantyx is a clinical genetic testing company focused on rare disease diagnosis using whole genome sequencing and AI-driven variant interpretation. Direct peer with similar focus on rare disease and comparable technology approach.
• Natera: Natera is a US-based genetic testing company offering reproductive and oncology genetic tests. Direct peer in advanced genetic testing with strong AI/machine learning capabilities and similar technology-driven value proposition.

Broad incumbents

• Ambry Genetics: Ambry Genetics (acquired by Konica Minolta) is an established US clinical genetic testing lab offering comprehensive hereditary disease testing. Broad incumbent with larger scale and broader test menu including rare disease panels.
• Myriad Genetics: Myriad Genetics is a major genetic testing and precision medicine company with a long history in hereditary cancer and other genetic tests. Broad incumbent with diversified product portfolio and established US market presence.
• Illumina: Illumina is the dominant DNA sequencing technology provider whose platforms 3billion uses (NovaSeq X). Broad incumbent in genomics ecosystem; a critical technology partner and indirect competitor as Illumina expands into clinical diagnostics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UC2ChgM_MBbg0afknks8KNvw
• Facebookfacebook.com/3billion
• LinkedInlinkedin.com/company/3billion
• Xx.com/3billionrare

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 3billion